We’re here to make an impact. At Ocugen, we approach drug development with a sense of urgency, resolve, ingenuity, and boldness. We consider patients in everything we do. Courageous innovation means driving science in new directions and breaking new ground.
Scientific Platforms
PIPELINE
-
Asset/ Program
OCU400AAV-hNR2E3
Received orphan drug designationsIndication
Treatment of retinitis pigmentosa—RHO Mutations and gene-agnostic
Phase
Phase 3
-
Asset/ Program
OCU400AAV-hNR2E3
Received orphan drug designationsIndication
Treatment of Leber congenital amaurosis—CEP290 mutation
Phase
Phase 1/2
-
Asset/ Program
OCU410AAV-hRORA
Indication
Dry Age-Related Macular Degeneration (Geographic Atrophy)
Phase
Phase 1/2
-
-
Asset/ Program
OCU200Transferrin-Tumstatin
Indication
Diabetic Macular Edema, Diabetic Retinopathy and Wet Age-Related Macular Degeneration (Wet AMD)
Phase
IND Submitted*
-
Asset/ Program
NeoCart®(Autologous chondrocyte-derived neocartilage)
Indication
Treatment of Articular Cartilage Defects in the Knee
Phase
Phase 3**
-
Asset/ Program
OCU500Inhaled vaccine
Indication
For Prevention of Disease Caused by COVID-19
Phase
IND Planned***
-
Asset/ Program
OCU510Quadrivalent inhaled vaccine
Indication
For Prevention of Disease Caused by Flu
Phase
IND Planned
-
Asset/ Program
OCU520Combination quadrivalent flu COVID-19 inhaled vaccine
Indication
For Prevention of Disease Caused by Flu and COVID-19
Phase
IND Planned
*Continue to work with FDA to address comments to lift the clinical hold
**Phase 3 clinical trial is planned for 2H 2024, contingent on funding availability
***OCU500 IND planned for mid-2024 in collaboration with NIAID